The Latest RoboSense LiDAR Perception Solution Will Support Robo Taxi Development
4.12.2019 17:00:00 EET | Business Wire | Press release
RoboSense today announced its launch of a developed and complete LiDAR perception solution for Robo Taxi (RS-Fusion-P5) in markets outside China. The RS-Fusion-P5 was first launched in China last month. Equipped with an RS-Ruby and four RS-BPearl, The RS-Fusion-P5 is considered to be the alternative to Waymo's LiDAR solution, further accelerating the development of Robo Taxi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005271/en/
(Graphic: Business Wire)
Full Coverage, Zero Blind Spots In The Range Of 200 Meters
RoboSense RS-Fusion-P5 uses an RS-Ruby on top of the vehicle to ensure a sensing range with a radius of more than 200 meters. However, even if the vertical field of view (FOV) of RS-Ruby reaches the perfect angles from -25° to +15°, there is still a small blind zone around the vehicle body. Therefore, to cover the small blind zone, 4 RS-BPearl embedded sideways around the vehicle form a hemisphere FOV scanning area relative to the vehicle's perspective, to guarantee a complete 360° surrounding view.
Empowers Level 4 Or Above Autonomous Vehicles With Full-stack Perception Capabilities
The RS-Fusion-P5 solution fuses point clouds from RS-Ruby and RS-BPearl in real-time, and generate laser points of more than 4,600,000pts per second.
Through its advanced AI perception algorithms, multi-sensor fusion and synchronization interfaces, vehicles are able to identify all-around obstacles and position easily and precisely.
The Main RS-Ruby With 0.1 ° Vertical Resolution, 200m @ 10% Ranging Ability
RS-Ruby achieves the anti-interference of multiple LiDAR using special laser encryption technology to filter interference signals. Meanwhile, it is not affected by the strongest direct-sunlight. Its LiDAR reflection intensity reaches a perfect balance of consistency and distinction.
RS-BPearl Reaches The Minimum Detection Range Of Less Than 5cm
The embedded four RS-BPearl form a hemispherical FOV coverage of 90 ° * 360 °, which not only can precisely identify objects around the vehicle body such as pets, children, roadbeds as well as other details of the near-field ground area, but also detect the actual height information under particular scenarios such as bridge tunnels and culverts, further supporting autonomous vehicles for driving decision making and greatly improving car safety.
The RS-Fusion-P5 is able to reach 200m detection range, 0.1° high-precision resolution with full coverage, zero blind spots in the sensing zone. It is one of the leading and developed automotive LiDAR solution for Robo Taxi available on the market. More details of RS-Fusion-P5 can be found at http://www.robosense.cn/rslidar/rs-fusion-p5.
Meanwhile, RoboSense wins CES 2020 Innovation Award for autonomous vehicle technology, and will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About RoboSense:
The world’s leading autonomous driving LiDAR perception solution provider, RoboSense, supplies LiDAR technologies to a wide range of domestic and international autonomous driving technology companies, OEMs, and tier 1 suppliers. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, ControlWorks, Aidrivers, and more. In China, RoboSense has received more than 300 million RMB in strategic investments from Alibaba’s Cainiao Network, SAIC, and BAIC, making RoboSense Asia’s number one LiDAR company, with the largest funding in China’s LiDAR industry. RoboSense has won numerous international awards, including the CES 2020 and 2019 Innovation Awards, the 2019 AutoSens Award, and the 2019 Stevie Award - Gold Award. For more information on RoboSense, see the website at http://www.robosense.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005271/en/
Contact information
Media:
Cassie Gong
RoboSense PR Manager
sqgong@robosense.cn
86-18620031448
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom